Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation

Hung Nguyen1, Hoang Linh Nguyen2,3, Pham Dang Lan4,5

  • 1Institute of Physics, Polish Academy of Sciences, al. Lotnikow 32/46, 02-668 Warsaw, Poland. masli@ifpan.edu.pl.

Chemical Society Reviews
|August 31, 2023
PubMed

Insights

Understanding the molecular interactions of SARS-CoV-2, including its spike protein and ACE2 receptor, is crucial for developing effective COVID-19 treatments and addressing vaccine side effects against emerging variants.

Area of Science:

  • Virology
  • Immunology
  • Computational Biology

Background:

  • The COVID-19 pandemic, caused by SARS-CoV-2, has spurred rapid vaccine and drug development.
  • Emerging variants like Delta and Omicron pose ongoing challenges to public health.
  • A deeper understanding of molecular interactions is needed for improved therapeutics and to explain vaccine side effects.

Purpose of the Study:

  • To investigate the molecular interactions of SARS-CoV-2 with human cells and therapeutic agents.
  • To focus on the structure of SARS-CoV-2 and its spike protein-ACE2 interaction.
  • To explore other viral entry mechanisms and the virus's impact on host cell processes.

Main Methods:

  • Computational approaches to analyze SARS-CoV-2 structure.
  • Examination of spike protein binding to human ACE2 and other potential receptors.
  • Analysis of viral-host membrane fusion and antibody/nanobody interactions.
  • Investigation of SARS-CoV-2 effects on host protein synthesis.

Main Results:

  • Detailed structural analysis of SARS-CoV-2 and its spike protein.
  • Identification of key interactions at the ACE2 receptor.
  • Exploration of viral entry pathways and immune evasion mechanisms.
  • Assessment of the impact on host cellular machinery.

Conclusions:

  • Computational analysis provides critical insights into SARS-CoV-2 molecular mechanisms.
  • Understanding spike protein interactions is vital for combating COVID-19 and its variants.
  • Further research into viral-host interactions will guide the development of next-generation therapeutics.